全文获取类型
收费全文 | 6358篇 |
免费 | 474篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 102篇 |
妇产科学 | 65篇 |
基础医学 | 1051篇 |
口腔科学 | 44篇 |
临床医学 | 773篇 |
内科学 | 1757篇 |
皮肤病学 | 88篇 |
神经病学 | 564篇 |
特种医学 | 225篇 |
外科学 | 853篇 |
综合类 | 20篇 |
预防医学 | 500篇 |
眼科学 | 45篇 |
药学 | 360篇 |
中国医学 | 9篇 |
肿瘤学 | 355篇 |
出版年
2023年 | 30篇 |
2022年 | 39篇 |
2021年 | 173篇 |
2020年 | 89篇 |
2019年 | 161篇 |
2018年 | 180篇 |
2017年 | 104篇 |
2016年 | 117篇 |
2015年 | 179篇 |
2014年 | 251篇 |
2013年 | 298篇 |
2012年 | 494篇 |
2011年 | 478篇 |
2010年 | 278篇 |
2009年 | 254篇 |
2008年 | 434篇 |
2007年 | 442篇 |
2006年 | 427篇 |
2005年 | 445篇 |
2004年 | 407篇 |
2003年 | 404篇 |
2002年 | 395篇 |
2001年 | 65篇 |
2000年 | 53篇 |
1999年 | 89篇 |
1998年 | 89篇 |
1997年 | 59篇 |
1996年 | 48篇 |
1995年 | 50篇 |
1994年 | 43篇 |
1993年 | 18篇 |
1992年 | 24篇 |
1991年 | 24篇 |
1990年 | 38篇 |
1989年 | 27篇 |
1988年 | 28篇 |
1987年 | 20篇 |
1986年 | 18篇 |
1985年 | 10篇 |
1984年 | 12篇 |
1983年 | 8篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1975年 | 4篇 |
1973年 | 7篇 |
1972年 | 3篇 |
1971年 | 6篇 |
1966年 | 3篇 |
排序方式: 共有6864条查询结果,搜索用时 203 毫秒
71.
Florence Pasquier Didier Leys Henri Petit 《Cephalalgia : an international journal of headache》1987,7(3):169-170
The patient reported had had a continuous headache involving the whole skull for 7 years. Many drugs had failed to relieve the pain, but with indomethacin the headache completely disappeared within 3 days. Nine months later the treatment was discontinued without any relapse. This variety of headache, not previously reported, was quite similar to the "hemicrania continua" except for its localization. 相似文献
72.
Xiaoyu Wang Mingzhen Zhang Regina R. Woloshun Yang Yu Jennifer K. Lee Shireen R. L. Flores Didier Merlin James F. Collins 《Nutrients》2021,13(5)
Intestinal iron transport requires an iron importer (Dmt1) and an iron exporter (Fpn1). The hormone hepcidin regulates iron absorption by modulating Fpn1 protein levels on the basolateral surface of duodenal enterocytes. In the genetic, iron-loading disorder hereditary hemochromatosis (HH), hepcidin production is low and Fpn1 protein expression is elevated. High Fpn1-mediated iron export depletes intracellular iron, causing a paradoxical increase in Dmt1-mediated iron import. Increased activity of both transporters causes excessive iron absorption, thus initiating body iron loading. Logically then, silencing of intestinal Dmt1 or Fpn1 could be an effective therapeutic intervention in HH. It was previously established that Dmt1 knock down prevented iron-loading in weanling Hamp (encoding hepcidin) KO mice (modeling type 2B HH). Here, we tested the hypothesis that Dmt1 silencing combined with dietary iron restriction (which may be recommended for HH patients) will mitigate iron loading once already established. Accordingly, adult Hamp KO mice were switched to a low-iron (LFe) diet and (non-toxic) folic acid-coupled, ginger nanoparticle-derived lipid vectors (FA-GDLVs) were used to deliver negative-control (NC) or Dmt1 siRNA by oral, intragastric gavage daily for 21 days. The LFe diet reduced body iron burden, and experimental interventions potentiated iron losses. For example, Dmt1 siRNA treatment suppressed duodenal Dmt1 mRNA expression (by ~50%) and reduced serum and liver non-heme iron levels (by ~60% and >85%, respectively). Interestingly, some iron-related parameters were repressed similarly by FA-GDLVs carrying either siRNA, including 59Fe (as FeCl3) absorption (~20% lower), pancreatic non-heme iron (reduced by ~65%), and serum ferritin (decreased 40–50%). Ginger may thus contain bioactive lipids that also influence iron homeostasis. In conclusion, the combinatorial approach of FA-GDLV and Dmt1 siRNA treatment, with dietary iron restriction, mitigated pre-existing iron overload in a murine model of HH. 相似文献
73.
Stacey Rolak Arjang Djamali Didier A. Mandelbrot Brenda L. Muth Margaret R. Jorgenson Weixiong Zhong Patricia Liu Brad C. Astor Sandesh Parajuli 《Transplantation proceedings》2021,53(5):1462-1469
Delayed graft function (DGF) after kidney transplantation is associated with an increased risk of graft failure. We studied the histologic findings among adult kidney transplant recipients transplanted between January 2000 and June 2015 who had DGF and had a kidney biopsy within 14 days of transplant. Death censored graft failure (DCGF) and death at 1 and 3 years after transplant were examined. A total of 269 transplant recipients fulfilled our selection criteria, of which 152 (56.51%) had acute tubular necrosis (ATN), 44 (16.4%) had acute rejection (AR), mainly T-cell mediated rejection (n = 31), 35 (13%) had ATN with AR (mainly T-cell mediated rejection, n = 26), and 38 (14.1%) had other pathology. Compared with those with ATN alone, kidney transplant recipients with AR alone had a significantly higher risk of DCGF at 1 year post transplant (adjusted hazard ratio = 3.70; 95% confidence interval 1.5-9.5; P = .006). Those with AR alone had an increased risk of DCGF at 3 years post transplant (hazard ratio = 3.10; 95% confidence interval 1.3-8.5; P = .01) in crude analyses. There was no association between DGF etiology and mortality. Early renal biopsy can be used to distinguish AR, which has protocolized treatments, from other etiologies. This could potentially alter allograft survival within 1 year of transplant complicated by DGF. 相似文献
74.
75.
David P. Al-Adra Laura Hammel John Roberts E. Steve Woodle Deborah Levine Didier Mandelbrot Elizabeth Verna Jayme Locke Jonathan D'Cunha Maryjane Farr Deirdre Sawinski Piyush K. Agarwal Jennifer Plichta Sandhya Pruthi Deborah Farr Richard Carvajal John Walker Fiona Zwald Thomas Habermann Morie Gertz Philip Bierman Don S. Dizon Carrie Langstraat Talal Al-Qaoud Scott Eggener John P. Richgels George J. Chang Cristina Geltzeiler Gonzalo Sapisochin Rocco Ricciardi Alexander S. Krupnick Cassie Kennedy Nisha Mohindra David P. Foley Kymberly D. Watt 《American journal of transplantation》2021,21(2):460-474
Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of malignancy. Although the cancer has been treated in these patients, the benefits of transplantation need to be balanced against the risk of tumor recurrence, especially in the setting of immunosuppression. Prior guidelines of when to transplant patients with a prior treated malignancy do not take in to account current staging, disease biology, or advances in cancer treatments. To develop contemporary recommendations, the American Society of Transplantation held a consensus workshop to perform a comprehensive review of current literature regarding cancer therapies, cancer stage-specific prognosis, the kinetics of cancer recurrence, and the limited data on the effects of immunosuppression on cancer-specific outcomes. This document contains prognosis based on contemporary treatment and transplant recommendations for breast, colorectal, anal, urological, gynecological, and nonsmall cell lung cancers. This conference and consensus documents aim to provide recommendations to assist in the evaluation of patients for SOT given a history of a pretransplant malignancy. 相似文献
76.
Thierry Tiendrebeogo Eugne Messou Shino Arikawa Didier K Ekouevi Aristophane Tanon Vivian Kwaghe Eric Balestre Marcel Djimon Zannou Armel Poda Franois Dabis Antoine Jaquet Albert Minga Renaud Becquet IeDEA West Africa Collaboration 《Journal of the International AIDS Society》2021,24(5)
IntroductionSex differences have already been reported in sub‐Saharan Africa for attrition and immunological response after antiretroviral therapy (ART) initiation, but follow‐up was usually limited to the first two to three years after ART initiation. We evaluated sex differences on the same outcomes in the 10 years following ART initiation in West African adults.MethodsWe used cohort data of patients included in the IeDEA West Africa collaboration, who initiated ART between 2002 and 2014. We modelled no‐follow‐up and 10‐year attrition risks, and immunological response by sex using logistic regression analysis, survival analysis with random effect and linear mixed models respectively.ResultsA total of 71,283 patients (65.8% women) contributed to 310,007 person‐years of follow‐up in 16 clinics in eight West African countries. The cumulative attrition incidence at 10‐year after ART initiation reached 75% and 68% for men and women respectively. Being male was associated with an increased risk of no follow‐up after starting ART (5.1% vs. 4.0%, adjusted Odds Ratio: 1.25 [95% CI: 1.15 to 1.35]) and of 10‐year attrition throughout the 10‐year period following ART initiation: adjusted Hazard Ratios were 1.22 [95% CI: 1.17 to 1.27], 1.08 [95% CI: 1.04 to 1.12] and 1.04 [95% CI: 1.01 to 1.08] during year 1, years 2 to 4 and 5 to 10 respectively. A better immunological response was achieved by women than men: monthly CD4 gain was 30.2 and 28.3 cells/mL in the first four months and 2.6 and 1.9 cells/μL thereafter. Ultimately, women reached the average threshold of 500 CD4 cells/μL in their sixth year of follow‐up, whereas men failed to reach it even at the end of the 10‐year follow‐up period. The proportion of patients reaching the threshold was much higher in women than in men after 10 years since ART initiation (65% vs. 44%).ConclusionsIn West Africa, attrition is unacceptably high in both sexes. Men are more vulnerable than women on both attrition and immunological response to ART in the 10 years following ART initiation. Innovative tracing strategies that are sex‐adapted are needed for patients in care to monitor attrition, detect early high‐risk groups so that they can stay in care with a durably controlled infection. 相似文献
77.
78.
Aziz Elimadi Didier Morin Edith Albengres Anne-Marie Chauvet-Monges Valérie Allain Aimé Crevat Jean-Paul Tillement 《British journal of pharmacology》1997,121(7):1295-1300
- The effects of zidovudine (ZDV) and zidovudine triphosphate (ZDV-3P) on Ca2+-induced mitochondrial permeability transition (MPT), respiratory control ratio (RCR) and ATP synthesis have been investigated on isolated rat liver mitochondria.
- ZDV slightly but significantly decreased RCR and ATP synthesis but was ineffective in inhibiting MPT. In contrast, ZDV-3P did not alter RCR and ATP synthesis but strongly inhibited MPT (IC50=3.0±0.9 μM).
- The effect of ZDV-3P on mitochondrial swelling required a preincubation time. When incubated 10 min with mitochondria, ZDV-3P (8 μM) totally inhibited the rate of swelling.
- ADP, ATP and atractyloside, which are agents known to interact with the mitochondrial adenine nucleotide carrier (ANC), antagonized the effect of ZDV-3P on mitochondrial swelling. Indeed, the IC50 value of ZDV-3P increased from 3.0 to 17.4, 93.6 and 66.5 μM, in the presence of 20 μM, ADP, ATP or atractyloside, respectively.
- ZDV-3P did not displace [3H]-ATP from its mitochondrial binding site(s) whereas ADP and atractyloside did, suggesting that ZDV-3P and [3H]-ATP do not share the same binding sites.
- ZDV-3P did not affect either mitochondrial respiration or ATP synthesis but inhibited Ca2+-dependent mitochondrial swelling. It was concluded that mitochondrial toxic effects observed during the chronic administration of ZDV cannot be related to its active metabolite (ZDV-3P).
79.
80.